Compare Stocks → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:AGECVE:EGACVE:NGZNASDAQ:PSM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGEAgeX Therapeutics$2.58$11.07▼$35.71$11.96M1.189,164 shs3,753 shsEGAEagle GraphiteC$0.09+6.3%C$0.08C$0.07▼C$0.22C$3.22MN/A13,933 shs9,003 shsNGZLithium South Development Co. (NGZ.V)C$0.31-8.8%C$0.31C$0.05▼C$0.49C$8.62MN/A25,841 shs4,000 shsPSMPrincipal U.S. Small-MidCap Multi-Factor ETF$29.53$29.53$15.33▼$29.53$11.81MN/A921 shsN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGEAgeX Therapeutics0.00%-14.68%+4,693.52%+4,442.20%+2,787.80%EGAEagle Graphite0.00%0.00%0.00%0.00%0.00%NGZLithium South Development Co. (NGZ.V)0.00%0.00%0.00%0.00%0.00%PSMPrincipal U.S. Small-MidCap Multi-Factor ETF0.00%0.00%0.00%0.00%0.00%How you can target big results without spending big money! (Ad)While most folks are paying $500… $1,000… Or even MORE to trade popular stocks like Apple, Nvidia, or Microsoft… I’ve discovered a new way to tap into what could be the cheapest options on the market… I’m talking about the $0.25 Cent Trades! Click here so I can share the details of my $0.25 Cent TradesMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGEAgeX TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AEGAEagle GraphiteN/AN/AN/AN/AN/AN/AN/AN/ANGZLithium South Development Co. (NGZ.V)N/AN/AN/AN/AN/AN/AN/AN/APSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGEAgeX TherapeuticsN/AN/AN/AN/AEGAEagle GraphiteN/AN/AN/AN/ANGZLithium South Development Co. (NGZ.V)N/AN/AN/AN/APSMPrincipal U.S. Small-MidCap Multi-Factor ETF0.00N/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGEAgeX Therapeutics$140K0.00N/AN/A($16.07) per share0.00EGAEagle GraphiteN/AN/AC$0.00 per share85.00C($0.11) per shareN/ANGZLithium South Development Co. (NGZ.V)N/AN/AC$0.00 per share310.00C$0.17 per shareN/APSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGEAgeX Therapeutics-$14.80M-$13.030.00N/AN/A-10,424.65%N/A-120.90%3/29/2024 (Estimated)EGAEagle GraphiteN/A-C$0.01N/A∞N/AN/AN/AN/AN/ANGZLithium South Development Co. (NGZ.V)N/A-C$0.21N/A∞N/AN/AN/AN/AN/APSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/AN/A0.00∞N/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGEAgeX TherapeuticsN/AN/AN/AN/AN/AEGAEagle GraphiteN/AN/AN/AN/AN/ANGZLithium South Development Co. (NGZ.V)N/AN/AN/AN/AN/APSMPrincipal U.S. Small-MidCap Multi-Factor ETF$0.431.46%N/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGEAgeX TherapeuticsN/A0.130.36EGAEagle GraphiteN/A0.010.01NGZLithium South Development Co. (NGZ.V)4.800.350.09PSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGEAgeX Therapeutics12.50%EGAEagle GraphiteN/ANGZLithium South Development Co. (NGZ.V)N/APSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/AInsider OwnershipCompanyInsider OwnershipAGEAgeX Therapeutics6.50%EGAEagle GraphiteN/ANGZLithium South Development Co. (NGZ.V)N/APSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGEAgeX Therapeutics51.08 million1.01 millionNot OptionableEGAEagle GraphiteN/A37.85 millionN/ANot OptionableNGZLithium South Development Co. (NGZ.V)N/A27.79 millionN/ANot OptionablePSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/A400,000N/ANot OptionableEGA, PSM, NGZ, and AGE HeadlinesNo headlines for this company have been tracked by MarketBeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesPalantir Technologies: Bearish Sentiment, Bullish Chart SignalsMarch 27, 2024 7:30 AMView Palantir Technologies: Bearish Sentiment, Bullish Chart SignalsApple Faces DOJ Scrutiny, but Not These 3 Under the Radar NamesMarch 25, 2024 9:46 AMView Apple Faces DOJ Scrutiny, but Not These 3 Under the Radar NamesTrump Media & Technology Group Soars on Market DebutMarch 26, 2024 1:05 PMView Trump Media & Technology Group Soars on Market DebutCan WeightWatchers Regain its Mojo after Oprah Steps Down? March 13, 2024 7:04 AMView Can WeightWatchers Regain its Mojo after Oprah Steps Down? JD.com Stock Is Back to 2018 Prices, Earnings Set to Beat PeersMarch 6, 2024 8:09 AMView JD.com Stock Is Back to 2018 Prices, Earnings Set to Beat PeersAll Headlines Company DescriptionsAgeX TherapeuticsNYSE:AGEAgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.Eagle GraphiteCVE:EGAEagle Graphite Incorporated, together with its subsidiaries, engages in the acquisition, exploration, and development of graphite properties in Canada. The company holds an interest in the Black Crystal project located in the city of Nelson in British Columbia. As of May 31, 2021, it owned 6 mineral tenures covering an area of approximately 1,412 hectares of land near Nelson, British Columbia. The company is based in Toronto, Canada.Lithium South Development Co. (NGZ.V)CVE:NGZNRG Metals Inc., an exploration stage junior mining company, engages in the identification, acquisition, and exploration of mineral properties. Its flagship property is the Hombre Muerto North lithium brine project covering approximately 3,287 hectares in 6 mining concessions located in Salta Province, Argentina. The company was formerly known as Codrington Resource Corporation and changed its name to NRG Metals Inc. in September 2015. NRG Metals Inc. was incorporated in 1995 and is headquartered in Vancouver, Canada.Principal U.S. Small-MidCap Multi-Factor ETFNASDAQ:PSM Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.